menu
    • menu

    Find Ziconotide Acetate manufacturers, exporters & distributors on PharmaCompass

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    4

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    1

    NDC API

    NDC API

    0

    VMF

    NDC API

    3

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 7,402,310

    MARKET PLACE

    0

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    7

    FDF Dossiers

    FDF Dossiers

    4

    FDA Orange Book

    FDA (Orange Book)

    1

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    2

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    20

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    1

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    107,552

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    3 RELATED EXCIPIENT COMPANIES

    3EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 107452-89-1, Conotoxin mviia, Omega-conotoxinmviia, Schembl676878, Akos015896032, Ncgc00181313-01
    Molecular Formula
    C102H172N36O32S7
    Molecular Weight
    2639.2  g/mol
    InChI Key
    BPKIMPVREBSLAJ-UHFFFAOYSA-N
    Ziconotide Acetate
    1 2D Structure

    Ziconotide Acetate

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[63-amino-13,45,54,60-tetrakis(4-aminobutyl)-4,36-bis(3-carbamimidamidopropyl)-16-carbamoyl-71-(1-hydroxyethyl)-7,39,77-tris(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-48-methyl-33-(2-methylpropyl)-30-(2-methylsulfanylethyl)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-tetracosaoxo-18,19,65,66,81,82-hexathia-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosazatricyclo[40.37.4.221,68]pentaoctacontan-24-yl]acetic acid
    2.1.2 InChI
    InChI=1S/C102H172N36O32S7/c1-50(2)34-63-91(161)127-62(26-33-171-5)90(160)129-64(35-53-22-24-54(143)25-23-53)92(162)130-65(36-78(148)149)93(163)135-72-48-175-173-45-69(80(108)150)133-86(156)58(18-8-12-29-105)121-76(146)39-117-85(155)66(41-139)131-88(158)61(21-15-32-114-102(111)112)126-96(166)70-46-176-177-47-71(97(167)132-68(43-141)95(165)125-60(87(157)128-63)20-14-31-113-101(109)110)134-89(159)59(19-9-13-30-106)123-81(151)51(3)119-74(144)37-115-83(153)56(16-6-10-27-103)120-75(145)38-116-84(154)57(17-7-11-28-104)124-82(152)55(107)44-172-174-49-73(137-98(72)168)99(169)138-79(52(4)142)100(170)118-40-77(147)122-67(42-140)94(164)136-70/h22-25,50-52,55-73,79,139-143H,6-21,26-49,103-107H2,1-5H3,(H2,108,150)(H,115,153)(H,116,154)(H,117,155)(H,118,170)(H,119,144)(H,120,145)(H,121,146)(H,122,147)(H,123,151)(H,124,152)(H,125,165)(H,126,166)(H,127,161)(H,128,157)(H,129,160)(H,130,162)(H,131,158)(H,132,167)(H,133,156)(H,134,159)(H,135,163)(H,136,164)(H,137,168)(H,138,169)(H,148,149)(H4,109,110,113)(H4,111,112,114)
    2.1.3 InChI Key
    BPKIMPVREBSLAJ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1C(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)NC(C(=O)NCC(=O)NC(C(=O)N3)CO)C(C)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN
    2.2 Synonyms
    2.2.1 Depositor-Supplied Synonyms

    1. 107452-89-1

    2. Conotoxin Mviia

    3. Omega-conotoxinmviia

    4. Schembl676878

    5. Akos015896032

    6. Ncgc00181313-01

    7. Ft-0675902

    8. Q198473

    2.3 Create Date
    2007-07-03
    3 Chemical and Physical Properties
    Molecular Weight 2639.2 g/mol
    Molecular Formula C102H172N36O32S7
    XLogP3-14
    Hydrogen Bond Donor Count42
    Hydrogen Bond Acceptor Count46
    Rotatable Bond Count40
    Exact Mass2638.1016905 g/mol
    Monoisotopic Mass2637.0983357 g/mol
    Topological Polar Surface Area1310 Ų
    Heavy Atom Count177
    Formal Charge0
    Complexity5480
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count22
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NamePrialt
    PubMed HealthZiconotide (Into the fluid around your spinal cord and brain)
    Drug ClassesAnalgesic
    Drug LabelPRIALT contains ziconotide, a synthetic equivalent of a naturally occurring conopeptide found in the piscivorous marine snail, Conus magus. Ziconotide is a 25amino acid, polybasic peptide containing three disulfide bridges with a molecular weight o...
    Active IngredientZiconotide acetate
    Dosage FormInjectable
    RouteIntrathecal
    Strength500mcg/5ml (100mcg/ml); 500mcg/20ml (25mcg/ml); 100mcg/1ml (100mcg/ml)
    Market StatusPrescription
    CompanyJazz Pharms Intl

    2 of 2  
    Drug NamePrialt
    PubMed HealthZiconotide (Into the fluid around your spinal cord and brain)
    Drug ClassesAnalgesic
    Drug LabelPRIALT contains ziconotide, a synthetic equivalent of a naturally occurring conopeptide found in the piscivorous marine snail, Conus magus. Ziconotide is a 25amino acid, polybasic peptide containing three disulfide bridges with a molecular weight o...
    Active IngredientZiconotide acetate
    Dosage FormInjectable
    RouteIntrathecal
    Strength500mcg/5ml (100mcg/ml); 500mcg/20ml (25mcg/ml); 100mcg/1ml (100mcg/ml)
    Market StatusPrescription
    CompanyJazz Pharms Intl

    4.2 Therapeutic Uses

    Ziconotide is used intrathecally for the management of severe chronic pain in patients who are intolerant of or do not obtain adequate pain relief from other therapies (e.g., systemic analgesics, adjunctive therapies, intrathecal morphine therapy) when intrathecal therapy is warranted.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 2241

    4.3 Drug Warning

    /BOXED WARNING/ WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS. Prialt is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with Prialt. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue Prialt therapy in the event of serious neurological or psychiatric signs or symptoms.

    US Natl Inst Health (NIH); DailyMed. Current Medication Information. Prialt (Ziconotide) Injection, Solution. (Updated February 2013). Available from, as of April 24, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5449ca98-efb8-4c3b-8756-747b2349a472

    Meningitis has occurred in patients receiving ziconotide, principally in individuals receiving therapy via an external microinfusion device and catheter. Meningitis may occur secondary to inadvertent contamination of the microinfusion device or as a result of CSF seeding caused by hematogenous or direct spread from an infected pump pocket or catheter tract. Patients should be monitored for signs and symptoms of meningitis (e.g., fever, headache, stiff neck, altered mental status, nausea or vomiting, seizures). Preparation of ziconotide solution and filling of the drug reservoir should be performed under aseptic conditions by trained and qualified personnel. If meningitis is suspected (especially in immunocompromised patients) or is confirmed, appropriate measures (CSF culture, anti-infective therapy, removal of the microinfusion device and catheter) should be initiated.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 2241

    Use of Prialt has been associated with CNS-related adverse events, including psychiatric symptoms, cognitive impairment, and decreased alertness/unresponsiveness. For the 1254 patients treated /in clinical trials/, the following cognitive adverse event rates were reported: confusion (33%), memory impairment (22%), speech disorder (14%), aphasia (12%), thinking abnormal (8%), and amnesia (1%). Cognitive impairment may appear gradually after several weeks of treatment. The PRIALT dose should be reduced or discontinued if signs or symptoms of cognitive impairment develop, but other contributing causes should also be considered. The various cognitive effects of Prialt are generally reversible within 2 weeks after drug discontinuation. The medians for time to reversal of the individual cognitive effects ranged from 3 to 15 days. The elderly (> or = 65 years of age) are at higher risk for confusion.

    US Natl Inst Health (NIH); DailyMed. Current Medication Information. Prialt (Ziconotide) Injection, Solution. Feb, 2008. Available from, as of May 27, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6893

    Cognitive impairment (e.g., confusion, memory impairment, speech disorder, aphasia, abnormal thinking, amnesia) has been reported in patients receiving ziconotide. Cognitive impairment may appear gradually over several weeks and generally is reversible following discontinuance of the drug. If cognitive impairment develops, the dose of ziconotide should be reduced or the drug discontinued; other causes that could contribute to cognitive impairment should be considered.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 2241

    For more Drug Warnings (Complete) data for ZICONOTIDE (17 total), please visit the HSDB record page.

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Pharmacological Classes
    N-type Calcium Channel Antagonist [EPC]; N-Calcium Channel Receptor Antagonists [MoA]
    5.2 Absorption, Distribution and Excretion

    Ziconotide reached a maximal brain concentration of between 0.003 and 0.006% of the injected material per gram of tissue at 3-20 min after i.v. injection, and this decayed to below 0.001%/g after 2 hr. ... The peptide was perfused through in vivo dialysis probes implanted into the hippocampus. Image analysis and serial sectioning showed that diffusion of Ziconotide in the extracellular fluid around the dialysis probe was minimal, with the peptide located within 1 mm of the probe after 2 hr. ... Passage from blood to brain was also verified by in situ perfusion through the carotid artery. A statistically greater amount of radioactivity was found to cross the BBB after perfusion of radioiodinated Ziconotide compared to (14)C inulin.

    PMID:10822104 Newcomb R et al; Peptides 21 (4): 491-501(2000)

    The pharmacokinetics and pharmacodynamics of ziconotide were assessed over a 48-hour period following intrathecal (i.t.) administration (1, 5, 7.5, or 10 ug) to 22 patients with chronic, nonmalignant pain. Plasma and cerebrospinal fluid samples were obtained over a 24-hour period. Analgesic efficacy was monitored using Visual Analog Scale of Pain Intensity (VASPI) and Category Pain Relief Scores (CPRS) measurements. Pharmacokinetic (PK) parameters were calculated by noncompartmental methods. Plasma ziconotide data were insufficient for pharmacokinetic calculations. In cerebrospinal fluid, the median half-life of ziconotide was 4.5 hours. The median cerebrospinal fluid clearance and volume of distribution were 0.26 mL/min and 99 mL, respectively. Cerebrospinal fluid pharmacokinetics of ziconotide were linear, based on cumulative exposure and peak cerebrospinal fluid concentrations. A dose-related analgesia was observed. ...

    PMID:12817525 Wermeling D et al; J Clin Pharmacol 43 (6): 624-36 (2003)

    Intrathecal administration of ziconotide results in little systemic exposure. Following passage from the CSF into the systemic circulation, ziconotide is expected to be degraded to peptide fragments and their constituent amino acids by endopeptidases and exopeptidases present in most organs.

    American Society of Health System Pharmacists. AHFS Drug Information 2008. Bethesda, Maryland 2008, p. 2242

    Ziconotide is about 50% bound to human plasma proteins. The mean cerebrospinal fluid (CSF) volume of distribution (Vd) of ziconotide following intrathecal administration approximates the estimated total CSF volume (140 mL).

    US Natl Inst Health (NIH); DailyMed. Current Medication Information. Prialt (Ziconotide) Injection, Solution. Feb, 2008. Available from, as of May 27, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6893

    For more Absorption, Distribution and Excretion (Complete) data for ZICONOTIDE (6 total), please visit the HSDB record page.

    5.3 Metabolism/Metabolites

    Ziconotide is rapidly distributed and/or metabolized in spinal cerebrospinal fluid (CSF) after intrathecal administration, followed by relatively rapid mass transport of the product from the CSF into the plasma. The relative contributions of mass transport, within and outside the spinal cord, and metabolism within it, are unclear. There is certainly evidence for rapid transport into the blood and metabolism within the spinal cord is likely to have a significant role. Following entry into the blood, the compound is quickly metabolized by normal proteolytic mechanisms, eventually to its constituent amino acids; it can be assumed that these will be further metabolized or incorporated into proteins by normal processes.

    European Medicines Agency (EMEA); European Public Assessment Report (EPARs) for Authorized Medicinal Products for Human Use; Scientific Discussion; p.6 (February 28, 2008). Available from, as of May 28, 2008: https://www.emea.europa.eu/humandocs/PDFs/EPAR/Prialt/14122704en6.pdf

    Ziconotide is cleaved by endopeptidases and exopeptidases at multiple sites on the peptide. Following passage from the cerebrospinal fluid (CSF) into the systemic circulation during continuous IT administration, ziconotide is expected to be susceptible to proteolytic cleavage by various ubiquitous peptidases/proteases present in most organs (e.g., kidney, liver, lung, muscle, etc.), and thus readily degraded to peptide fragments and their individual constituent free amino acids. Human and animal CSF and blood exhibit minimal hydrolytic activity toward ziconotide in vitro. The biological activity of the various expected proteolytic degradation products of ziconotide has not been assessed.

    US Natl Inst Health (NIH); DailyMed. Current Medication Information. Prialt (Ziconotide) Injection, Solution. Feb, 2008. Available from, as of May 27, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6893

    5.4 Biological Half-Life

    The terminal half-life of ziconotide in cerebrospinal fluid after an intrathecal administration was around 4.6 hours (range 2.9-6.5 hours).

    US Natl Inst Health (NIH); DailyMed. Current Medication Information. Prialt (Ziconotide) Injection, Solution. Feb, 2008. Available from, as of May 27, 2008: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6893

    5.5 Mechanism of Action

    /Ziconotide/ is a N-type calcium channel blocker (NCCB). Voltage-sensitive calcium channel (VSCC) conduction plays a major role in the transmission of pain. The N-type VSCC's are found in high concentrations in the dorsal root ganglion cells responsible for the spinal processing of pain. Ziconotide selectively and reversibly binds to and blocks these channels without interacting with other ion channels or cholinergic, monoaminergic or mu and delta-opioid receptors. Ziconotide thus inhibits the spinal signalling of pain.

    European Medicines Agency (EMEA); European Public Assessment Report (EPARs) for Authorized Medicinal Products for Human Use; Scientific Discussion; p.1 (February 28, 2008). Available from, as of May 28, 2008: https://www.emea.europa.eu/humandocs/PDFs/EPAR/Prialt/14122704en6.pdf

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Import","activeIngredients":"ZICONOTIDE ACETATE","year":"2021","qtr":"Q1","strtotime":1613068200,"product":"ZICONOTIDE ACETATE API","address":"18\/1&3 AZAMABAD","city":"HYDERABAD ,ANDHRA PRADESH","supplier":"HYBIO PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"GUANGZHOU","customer":"BIOLOGICAL E","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"3500","totalValueFC":"4155.9","currency":"USD","unitRateINR":"605160","date":"12-Feb-2021","totalValueINR":"302580","totalValueInUsd":"4155.9","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"2744068","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"GUANGZHOU","supplierAddress":"","customerAddress":"18\/1&3 AZAMABAD"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722191400,"product":"ZICONOTIDE ACETATE","address":"6-3-865\/1\/2, FLAT NO.201,","city":"HYDERABAD, ANDHRA PRADESH","supplier":"CHEMWERTH INC","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"GLAND PHARMA LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.1","unit":"GMS","unitRateFc":"70000","totalValueFC":"10114.7","currency":"USD","unitRateINR":"8455000","date":"29-Jul-2024","totalValueINR":"845500","totalValueInUsd":"10114.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4760470","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"1764 LITCHFIELD TURNPIKESUITE 202WOODBRIDGE, CT, 06525, USA US","customerAddress":"6-3-865\/1\/2, FLAT NO.201,"}]
    12-Feb-2021
    29-Jul-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - INJECTABLE;INTRATHECAL - 100MCG/1ML ...DOSAGE - INJECTABLE;INTRATHECAL - 100MCG/1ML (100MCG/ML)

    USFDA APPLICATION NUMBER - 21060

    read-more

    DOSAGE - INJECTABLE;INTRATHECAL - 500MCG/5ML ...DOSAGE - INJECTABLE;INTRATHECAL - 500MCG/5ML (100MCG/ML)

    USFDA APPLICATION NUMBER - 21060

    read-more

    DOSAGE - INJECTABLE;INTRATHECAL - 500MCG/20ML...DOSAGE - INJECTABLE;INTRATHECAL - 500MCG/20ML (25MCG/ML)

    USFDA APPLICATION NUMBER - 21060

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Parenteral

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ziconotide Acetate Manufacturers

    A Ziconotide Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ziconotide Acetate, including repackagers and relabelers. The FDA regulates Ziconotide Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ziconotide Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Ziconotide Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Ziconotide Acetate Suppliers

    A Ziconotide Acetate supplier is an individual or a company that provides Ziconotide Acetate active pharmaceutical ingredient (API) or Ziconotide Acetate finished formulations upon request. The Ziconotide Acetate suppliers may include Ziconotide Acetate API manufacturers, exporters, distributors and traders.

    click here to find a list of Ziconotide Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Ziconotide Acetate USDMF

    A Ziconotide Acetate DMF (Drug Master File) is a document detailing the whole manufacturing process of Ziconotide Acetate active pharmaceutical ingredient (API) in detail. Different forms of Ziconotide Acetate DMFs exist exist since differing nations have different regulations, such as Ziconotide Acetate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Ziconotide Acetate DMF submitted to regulatory agencies in the US is known as a USDMF. Ziconotide Acetate USDMF includes data on Ziconotide Acetate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ziconotide Acetate USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Ziconotide Acetate suppliers with USDMF on PharmaCompass.

    Ziconotide Acetate NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ziconotide Acetate as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Ziconotide Acetate API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Ziconotide Acetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Ziconotide Acetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ziconotide Acetate NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Ziconotide Acetate suppliers with NDC on PharmaCompass.

    Ziconotide Acetate GMP

    Ziconotide Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Ziconotide Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ziconotide Acetate GMP manufacturer or Ziconotide Acetate GMP API supplier for your needs.

    Ziconotide Acetate CoA

    A Ziconotide Acetate CoA (Certificate of Analysis) is a formal document that attests to Ziconotide Acetate's compliance with Ziconotide Acetate specifications and serves as a tool for batch-level quality control.

    Ziconotide Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Ziconotide Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Ziconotide Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Ziconotide Acetate EP), Ziconotide Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ziconotide Acetate USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search